NGFR, also known as p75NTR, is a receptor of neurotrophins and involved in survival, differentiation and apoptosis of neurons. It is expressed in neuronal cells in various tissues and tumors with neuronal origin. Recent studies suggested that NGFR is also expressed in melanocytes, myoepithelial cells, basal-like cells, perivascular cells and lymphoid dendritic cells. NGFR is helpful in identification of perineural invasion of malignant skin tumors with a panel of antibodies. It is also a complementary marker to S-100 for identification of desmoplastic melanomas. In addition, NGFR may be used in identifying myoepithelial or basal-like cell differentiation in breast cancer.
Literature:
Manufacturer site:
NGFR (EP31)
Rabbit Monoclonal
NGFR, also known as p75NTR, is a receptor of neurotrophins and involved in survival, differentiation and apoptosis of neurons. It is expressed in neuronal cells in various tissues and tumors with neuronal origin. Recent studies suggested that NGFR is also expressed in melanocytes, myoepithelial cells, basal-like cells, perivascular cells and lymphoid dendritic cells. NGFR is helpful in identification of perineural invasion of malignant skin tumors with a panel of antibodies. It is also a complementary marker to S-100 for identification of desmoplastic melanomas. In addition, NGFR may be used in identifying myoepithelial or basal-like cell differentiation in breast cancer.
Rabbit Monoclonal
NGFR, also known as p75NTR, is a receptor of neurotrophins and involved in survival, differentiation and apoptosis of neurons. It is expressed in neuronal cells in various tissues and tumors with neuronal origin. Recent studies suggested that NGFR is also expressed in melanocytes, myoepithelial cells, basal-like cells, perivascular cells and lymphoid dendritic cells. NGFR is helpful in identification of perineural invasion of malignant skin tumors with a panel of antibodies. It is also a complementary marker to S-100 for identification of desmoplastic melanomas. In addition, NGFR may be used in identifying myoepithelial or basal-like cell differentiation in breast cancer.
